March 2018, Vol 11, Ninth Annual Payers' Guide

In 2017, the US Food and Drug Administration (FDA) approved 46 new drugs, a 21-year high.
The drugs included in this review were approved for the first time or received additional approvals by the US Food and Drug Administration in 2017 and are grouped here by several categories
Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma (NHL). Approximately 20% of all NHL cases are follicular lymphoma.
As knowledge of lung cancer tumor cell biology has evolved, small-molecule drugs that target specific genetic mutations offer oncologists the opportunity to treat patients with NSCLC in a personalized fashion.
Merkel cells are hormone-producing cells in the skin epidermis that relay touch-related information to the brain. Merkel-cell carcinoma is characterized by uncontrolled growth of skin cells with Merkel-cell features.
Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a cancer of the blood and bone marrow that affects the lymphocytes.
A recent addition to the treatment armamentarium for atopic dermatitis is the topical phosphodiesterase-4 inhibitor crisaborole (Eucrisa). In December 2016, the US Food and Drug Administration (FDA) approved crisaborole for the treatment of mild-to-moderate atopic dermatitis in patients aged ≥2 years.
Spasticity is a chronic condition that is characterized by an abnormal increase in tone or stiffness in ≥1 muscles that can interfere with movement and daily activities.
Approximately 22% of all non-Hodgkin lymphoma (NHL) cases are classified as follicular lymphoma, making it the second most common NHL subtype.
Page 1 of 4
Results 1 - 10 of 31
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME